Navigation Links
Pharmacopeia Announces Third Quarter 2007 Financial Results
Date:11/1/2007

e treatment of

hypertension and diabetic nephropathy. Findings from this study

also supported once-a-day oral dosing of PS433540 as the compound

successfully demonstrated its ability to block the angiotensin II-

induced blood pressure increase for 24 hours.

-- PS433540 demonstrated positive results in a multiple ascending dose

study. This safety and tolerability study was initially designed to

evaluate 14 days of daily dosing in healthy volunteers, at dose

levels of 50, 100, 250 and 500 mg of PS433540. As no safety or

tolerability issues were observed with any of these doses, the study

was expanded to include a 1,000 mg dose. As with previous lower

doses, there were no safety or tolerability issues observed with the

1,000 mg dose of PS433540.

-- Pharmacopeia announced that Bristol-Myers Squibb Company (BMS)

initiated a Phase 2 clinical trial with a p38 kinase inhibitor,

PS540446, that resulted from a collaborative research program between

the two companies. PS540446 is being evaluated for the oral treatment

of moderate to severe psoriasis.

-- Pharmacopeia announced that it earned a $1 million milestone payment

from Schering-Plough as the result of the initiation of a Phase 1

clinical trial in the United States for PS948115, a compound identified

from the collaboration between the two companies. The compound is

being evaluated as a potential treatment for respiratory disease.

Pharmacopeia is eligible to receive additional milestone payments for

PS540446 and PS948115 if the programs are advanced further in clinical

trials by BMS and Schering-Plough, respectively. The company will also

receive royalties on sales of any resulting therapeutic products

incorporating compounds derived from the progr
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma ... it will report its third quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
(Date:10/19/2014)... Große Pharmafirmen werden oft ... dabei ist, dass große Pharmafirmen nicht willens sind, ... Es war deshalb nicht einfach, diesen ... mehr, dass es uns gelungen ist! Wir haben ... - mit einem Vorbehalt - einige haben uns ...
(Date:10/17/2014)... , Oct. 17, 2014 With the ... Affairs function has come across several challenges in ... and managing globalization.  The ... is dedicated to providing benchmarking and best practices ... Consortium is a service composed of three stages: ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Inc. (Nasdaq: AUXL ) today announced that ... 31st Annual Health Care Conference during March 7-9, 2011 ... Chief Financial Officer, is scheduled to present an overview ... a.m. ET on Wednesday, March 9, 2011.   ...
... 2, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced that, ... determination from the NASDAQ Listing Qualifications Panel (the "Panel") ... for an extension to remain listed on The NASDAQ ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 3Nile Therapeutics Receives Positive NASDAQ Panel Decision 2Nile Therapeutics Receives Positive NASDAQ Panel Decision 3
(Date:10/20/2014)... The Advocator Group, LLC is ... Foundation for Suicide Prevention’s (AFSP) Out of the Darkness ... organization that hosts hundreds of community walks throughout the ... used to help understand and prevent suicide through not ... well. , The Advocator Group shares this passion ...
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
(Date:10/20/2014)... Myoderm announced today the ... their CentralSource service. Matthew will play ... drug sourcing, distribution, and management service for international ... of industry experience, in both business development and ... their international success to help clients manage their ...
(Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... BETHESDA, Md. (May 1, 2009) − Medical science took ... that, at least temporarily, perform the function of vital ... machine and renal dialysis, require the blood to be ... known as extracorporeal circulation (EC) and have provided critical ...
... in the May 1 issue of the journal SLEEP ... more likely to suffer from significant sleep disturbances at 2 ... of the study are of particular importance, as sleep disturbances ... depression in childhood. , Results indicate that infants ...
... who are wounded in combat as the result of a ... develop an abnormality known as heterotopic ossification. In this condition, ... near a fracture or other bone injury. New research conducted ... helping to pave the way for a better understanding of ...
... President pro Tem Darrell Steinberg (D-Sacramento) today announced ... Autism (ASD) & Related Disorders which will build ... the three-year California Legislative Blue Ribbon ... by Steinberg and ended in November 2008. ...
... (NYSE: BKD ) announced today that it plans to ... on Wednesday, May 6, 2009. The Company has also scheduled ... 2009 at 10:00 AM ET. The conference call can be ... 634-9069 (from outside of the U.S.) ten minutes prior to the ...
... news updates, features live, daily call-in shows hosted by world-class ... Ten Swine Flu FAQs at www.sirius.com/doctorradio , NEW ... (Nasdaq: SIRI ) has begun regular live updates ... health and medical channel powered by NYU Langone Medical Center. ...
Cached Medicine News:Health News:Chemical can reproduce complications for some patients 2Health News:Chemical can reproduce complications for some patients 3Health News:Chemical can reproduce complications for some patients 4Health News:Chemical can reproduce complications for some patients 5Health News:Maternal depression is associated with significant sleep disturbance in infants 2Health News:Injured Marines at risk for abnormal bone growth 2Health News:Steinberg Announces Senate Select Committee on Autism and Related Disorders 2Health News:Brookdale Announces First Quarter 2009 Release and Earnings Call 2Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 2Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 3Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 4Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 5Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 6
The Nine West Eyewear collection is positioned to present today's styles with a sharp, edgy contemporary attitude tied into a clean design element....
Inquire...
Inquire...
Inquire...
Medicine Products: